Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy

Angiology

Volumn 54, Issue 2, 2003, Pages 219-227

  Tallarico, Demetrio ^a   Rizzo, Vito ^a,c   Di Maio, Fernando ^a   Petretto, Federica ^a   Blanco, Gianluca ^a   Placanica, Giuseppe ^a   Marziali, Marta ^a   Paravati, Vincenzo ^a   Gueli, Nicolò ^a   Meloni, Fortunato ^a   Campbell, Stefano Villatico ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b 2nd Faculty of Medicine and Surgery   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; EPIRUBICIN; LIVER ENZYME; RAZOXANE; TRIMETAZIDINE;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CELL PROTECTION; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECELERATION; DIASTOLE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART MUSCLE; HEART MUSCLE RELAXATION; HEART PROTECTION; HUMAN; HYPERBILIRUBINEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; NEUTROPENIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTOLE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037345673     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970305400212     Document Type: Article

References (39)

1. Singh B: Mechanism of action of a novel metabolically active antianginal agent (trimetazidine) delineated by PET. J Am Coll Cardiol 27:132A, 1996.
2. Maridonneau Parini I, Harpey C: Effects of trimetazidine on membrane damage reduced by oxygen free radicals in human red cells. Br J Clin Pharmacol 20:148-151, 1985.
3. Detry JM, Sellier P, Pennaforte S, et al, on behalf of the Trimetazidine European Multicenter Study Group: Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 37:279-288, 1994.
4. Detry JM, Leclerq BS: Trimetazidine European multicenter study vs. propranolol in stable angina pectoris; contribution of Holter electrocardiographic ambulatory monitoring. Am J Cardiol 76:8B-11B, 1995.
5. Michaelides AP, Vyssoulis GP, Bonoris PE, et al: Beneficial effects of trimetazidine in men with stable angina under beta blocker treatment. Curr Ther Res 46:565-576, 1989.
6. Steg PG, Grollier G, Galley P, et al: A randomized double-blind trial of trimetazidine as adjunctive therapy to primary PTCA for acute myocardial infarction: evidence for improved myocardial reperfusion from ST-segment analysis. Eur Heart J 19:2046, 1998.
7. Kober G, Buck T, Sievert H, et al: Myocardial protection during percutaneous transluminal coronary angioplasty: Effects of trimetazidine. Eur Heart J 13:1109-1115, 1992.
8. Belardinelli M, Purcaro A: Trimetazidine improves the contractile response of hibernating myocardium to low-dose dobutamine in ischemic cardiomyopathy. Circulation 98:3727, 1998.
9. Lu C, Dabrowski P, Fragasso G, et al: Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 82:898-901, 1998.
10. Bristow MR, Billingham ME, Mason JW, et al: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62:873-879, 1978.
11. Schwartz R, Mc Kenzie W, Alexander J, et al: Congestive heart failure and left ventricular dysfunction complicating Doxorubicin therapy: A seven year experience using serial radionuclide angiocardiography. Am J Med 82:1109-1118, 1987.
12. Mortensen SA, Olsen HS, Baandrup U: Chronic anthracycline cardiotoxicity; hemodynamic and histopathological manifestations suggestive a restrictive endomyocardial disease. Br Heart J 55:274-282, 1986.
13. Praga C, Beretta G, Vigo PL: Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 63:827-834, 1979.
14. Von Hoff DD, Layard MW, Basa P: Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 91:710-717, 1979.
15. Speyer JL, Green MD, Zeleniuch Jacquotte A: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 10:117-127, 1982.
16. Venturini M, Michelotti A, Del Mastro L: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 14:3112: 3120, 1996.
17. Lopez M, Vici P: European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity. Semin Oncol 25(4 suppl):10:55-60, 1998.
18. Nishimura RA, Tajik AJ: Quantitative hemodynamics by Doppler echocardiography: A noninvasive alternative to cardiac catheterization. Progr Cardiovasc Dis 36:309-342, 1994.
19. Vasan RS, Benjamin EJ, Levy D: Prevalence, clinical features and prognosis of diastolic heart failure: An epidemiologic perspective. J Am Coll Cardiol 26:1565-1574, 1995.
20. European Study Group on Diastolic Heart Failure: How to diagnose diastolic heart failure. Eur Heart J 19:990-1003, 1998.
21. Takatsuji H, Mikami J, Urasawa K, et al: A new approach for evaluation of left ventricular diastolic function: Spatial and temporal analysis of left ventricular filling flow propagation by color M-mode Doppler echocardiography. J Am Coll Cardiol 27:365-371, 1996.
22. Lee BH, Goodenday LS, Muswick GJ, et al: Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol 9:184-188, 1987.
23. Marchandise B, Scroeder E, Bosly, et al: Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 118:92-98, 1989.
24. Brown KA, Blow AJ, Weiss RM, et al: Acute effects of doxorubicin on human left ventricular systolic and diastolic function. Am Heart J 118:92-98, 1989.
25. Alexander J, Dainiak N, Berger HJ, et al: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300:278-283, 1979.
26. Stoddard HF, Seeger J, Liddel NE, et al: Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 20:62-69, 1992.
27. Allen A: The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 19:529-542, 1992.
28. Lopez M, Vici P, Di Lauro L, et al: Randomized prospective clinical trial of high dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcoma. J Clin Oncol 16:89-92, 1998.
29. Levy S, Group of South France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am J Cardiol 76:6B-12B, 1995.
30. Fantini E, Demaison L, Sentax E, et al: Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocites during hypoxia and reoxygenation. J Mol Cell Cardiol 26:949-958, 1994.
31. Allibardi S, Chierchia SL, Cerioli V, et al: Trimetazidine reduces post-ischemic dysfunction in rat hearts by decreasing energy requirements during underperfusion. J Cardiovasc Pharmacol 22:640-647, 1998.
32. Detry MJ: TEMS: Double-blind comparison of trimetazidine and propranolol in stable angina pectoris. J Am Coll Cardiol 31:36-47, 1998.
33. Morin D, Sapena R, Elimadi A, et al: [(3)H]-trimetazidine mithocondrial binding sites: Regulation by cations, effect of trimetazidine derivatives and other agents and interaction with an endogenous substance. Br J Pharmacol 130:655-663, 2000.
34. Kantor PF, Lucien A, Kozak R, et al: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mithocondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 17;86(5):580-585, 2000.
35. Leandro J, Dyck J, Poppe D, et al: Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol 74:1152-1156, 1994.
36. Bu'Lock FA, Mott MG, Oakhill A, et al: Left ventricular diastolic function after anthracycline chemotherapy in childhood: Relation with systolic function, symptoms and pathophysiology. Br Heart J 73:340-350, 1995.
37. Cittadini A, Fazio S, D'Ascia C, et al: Subclinical cardiotoxicity by doxorubicin: A pulsed Doppler echocardiographic study. Eur Heart J 12:1000-1005, 1999.
38. Lefrak EA, Pitha J, Rosenheim S: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302-314, 1973.
39. Wyatt HL, Haendchen RV, Meerbaum S, et al: Assessment of quantitative methods for 2-dimensional echocardiography. Am J Cardiol 5:396-401, 1983.